文献速递腹部介入USMRCT

对比增强超声评估肝细胞癌化疗栓塞治疗反应:一项前瞻性多中心试验

Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial.
PubMed 文献 · Radiology · 2023-01-01

前瞻性多中心研究纳入132例拟行TACE的超声可见肝细胞癌患者,比较TACE后4-6周二维和三维CE US与CE MRI或CT检测残留存活肿瘤的诊断性能。结果显示二维CE US敏感度91%、三维CE US敏感度89%,均高于CE MRI或CT的68%;但CE MRI或CT特异度85%,高于二维CE US的70%和三维CE US的67%。CE US诊断性能不受随访时间影响。

要点

  • TACE后4-6周,二维CE US检测残留存活HCC的敏感度91%,高于CE MRI或CT的68%。
  • 三维CE US敏感度89%,与二维CE US无显著差异,但均高于CE MRI或CT。
  • CE MRI或CT特异度85%,高于二维CE US的70%和三维CE US的67%。

核心结论

  • TACE后4-6周二维和三维CE US检测残留HCC的敏感度高于CE MRI或CT,但特异度较低;CE US诊断性能不受随访时间影响。

研究设计与样本

  • 前瞻性多中心试验,2016年5月至2022年3月在三家学术医学中心连续纳入132例年龄≥21岁、超声可见HCC并计划行TACE的患者。

诊断标准与关键数值

  • TACE后4-6周二维CE US敏感度91%(95%CI:84,95),高于CE MRI或CT的68%(95%CI:58,76),P<.001。
  • TACE后4-6周三维CE US敏感度89%(95%CI:81,94),高于CE MRI或CT(P<.001),与二维CE US无显著差异(P=.22)。
  • CE MRI或CT特异度85%(95%CI:76,91),高于4-6周二维CE US的70%(95%CI:56,80;P=.046)和三维CE US的67%(95%CI:53,78;P=.023)。
  • TACE后1-2周与4-6周二维CE US各项诊断标准均无显著差异(P>.21)。

临床应用与阅片要点

  • TACE后4-6周行二维或三维CE US检测残留存活HCC的敏感度高于CE MRI或CT,但特异度较低。
  • CE US诊断性能在TACE后1-2周与4-6周之间无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Contrast-enhanced (CE) US has been studied for use in the detection of residual viable hepatocellular carcinoma (HCC) after locoregional therapy, but multicenter data are lacking. Purpose To compare two-dimensional (2D) and three-dimensional (3D) CE US diagnostic performance with that of CE MRI or CT, the current clinical standard, in the detection of residual viable HCC after transarterial chemoembolization (TACE) in a prospective multicenter trial. Materials and Methods Participants aged at least 21 years with US-visible HCC scheduled for TACE were consecutively enrolled at one of three participating academic medical centers from May 2016 to March 2022. Each underwent baseline 2D and 3D CE US before TACE, 2D and 3D CE US 1-2 weeks and/or 4-6 weeks after TACE, and CE MRI or CT 4-6 weeks after TACE. CE US and CE MRI or CT were evaluated by three fellowship-trained radiologists for the presence or absence of viable tumors and were compared with reference standards of pathology (18%), angiography on re-treatment after identification of residual disease at 1-2-month follow-up imaging (31%), 4-8-month CE MRI or CT (42%), or short-term (approximately 1-2 months) CE MRI or CT if clinically decompensated and estimated viability was greater than 50% at imaging (9%). Diagnostic performance criteria, including sensitivity and specificity, were obtained for each modality and time point with generalized estimating equation analysis. Results A total of 132 participants were included (mean age, 64 years ± 7 [SD], 87 male). Sensitivity of 2D CE US 4-6 weeks after TACE was 91% (95% CI: 84, 95), which was higher than that of CE MRI or CT (68%; 95% CI: 58, 76; P < .001). Sensitivity of 3D CE US 4-6 weeks after TACE was 89% (95% CI: 81, 94), which was higher than that of CE MRI or CT (P < .001), with no evidence of a difference from 2D CE US (P = .22). CE MRI or CT had 85% (95% CI: 76, 91) specificity, higher than that of 4-6-week 2D and 3D CE US (70% [95% CI: 56, 80] and 67% [95% CI: 53, 78], respectively; P = .046 and P = .023, respectively). No evidence of differences in any diagnostic criteria were observed between 1-2-week and 4-6-week 2D CE US (P > .21). Conclusion The 2D and 3D CE US examinations 4-6 weeks after TACE revealed higher sensitivity in the detection of residual HCC than CE MRI or CT, albeit with lower specificity. Importantly, CE US performance was independent of follow-up time. Clinical trial registration no. NCT02764801 © RSNA, 2023 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Savsani E, Shaw CM, Forsberg F, et al. Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial. Radiology. 2023. PMID: 37847138. doi:10.1148/radiol.230727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。